Biohit OyjLTS:0DRP +0.20%78 FCF Yield % is -4.53 as of Jun. 29, 2026. GuruFocus rates LTS:0DRP with a GF Score™ of 78/100 and a GF Value™ of €2.76 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Biohit Oyj ranks worse than 64.17% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Biohit Oyj's FCF Yield % or its related term are showing as below:
LTS:0DRP'
s FCF Yield % Range Over the Past 10 Years
Min: -4.58 Med: -0.2 Max: 7.15
Current: -4.53
During the past 13 years, the highest FCF Yield % of Biohit Oyj was 7.15%. The lowest was -4.58%. And the median was -0.20%.
LTS:0DRP's FCF Yield % is ranked worse than 64.17% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: -0.385
vs LTS:0DRP: -4.53
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Biohit Oyj FCF Yield % Related Terms
Biohit Oyj FCF Yield % Historical Data
* Premium members only.
The historical data trend for Biohit Oyj's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Biohit Oyj's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohit Oyj (LTS:0DRP) has a FCF Yield % of -4.53 as of Jun. 29, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Biohit Oyj and its competitors. According to the industry distribution chart, Biohit Oyj ranks #548 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 64.2%.
Is Biohit Oyj's FCF Yield % too high?
Biohit Oyj's current FCF Yield % is -4.53. Based on the distribution chart, Biohit Oyj ranks #548 out of 854 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Biohit Oyj has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's FCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #548 out of 854 companies for FCF Yield %. This places Biohit Oyj in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Biohit Oyj and its competitors. Biohit Oyj's current FCF Yield % is -4.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.76, compared to a current price of €2.47 — trading 10.5% below its estimated fair value. The current FCF Yield % is -4.53. Biohit Oyj's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current FCF Yield % is -4.53 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be undervalued.
The current stock price of €2.47 is trading 10.5% below its estimated GF Value™ of €2.76.
GuruFocus considers Biohit Oyj to be Modestly Undervalued.
Key valuation signals for LTS:0DRP:
FCF Yield %: -4.53
GF Value™: €2.76 vs. price of €2.47 (10.5% below fair value)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
78GF Score
Get the complete analysis for LTS:0DRP
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
